Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection

Won Tak Choi, Kuang-Yu Jen, Dongliang Wang, Mehdi Tavakol, John P. Roberts, Ryan M. Gill

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although donor livers with <30% large droplet macrovesicular steatosis (MaS) and/or small droplet MaS (irrespective of percentage) are considered safe to use, this consensus is based on variable definitions of MaS subtypes and/or without a reproducible scoring system. We analyzed 134 donor liver biopsies from allografts transplanted at University of California at San Francisco between 2000 and 2015 to determine whether large and/or small droplet MaS is a risk factor for poor outcomes. Large droplet MaS was defined as a fat droplet occupying greater than one half of an individual hepatocyte, with nuclear displacement, and scored as the percentage of total parenchymal area replaced by large fat droplets on ×40 magnification. Small droplet MaS was defined as 1 to several discrete fat droplets, each occupying less than one half of an individual hepatocyte, and scored as the percentage of remaining hepatocytes (ie, hepatocytes not occupied by large fat droplets) containing small fat droplets on ×200 magnification (ie, small droplet MaS is the percentage of "remaining hepatocytes" with small fat droplets, and "remaining hepatocytes" is defined as 100% minus percent large droplet MaS). Thus, total MaS equals the sum of large and small droplet MaS, which cannot exceed 100%. Electronic medical records were reviewed to determine outcomes. There was an increased risk for acute cellular rejection (hazard ratio=2.5, P=0.0108) and bile duct loss suggestive of chronic ductopenic rejection (hazard ratio=2.4, P=0.0130) in donor livers with ≥30% small droplet MaS. Large droplet MaS (up to 60%) was not associated with adverse outcomes. Patient survival was not adversely affected by steatosis. Excellent agreement on the estimation of large (weighted κ=0.682) and small droplet MaS (weighted κ=0.780) was achieved. Our approach to donor steatosis scoring can identify liver allograft recipients at increased risk for rejection and highlights the importance of distinguishing between small and large droplet MaS in this evaluation.

Original languageEnglish (US)
Pages (from-to)365-373
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume41
Issue number3
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Allografts
Hepatocytes
Fats
Liver
Tissue Donors
San Francisco
Electronic Health Records
Bile Ducts
Biopsy
Survival

Keywords

  • donor liver
  • liver transplantation
  • rejection
  • steatosis

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection. / Choi, Won Tak; Jen, Kuang-Yu; Wang, Dongliang; Tavakol, Mehdi; Roberts, John P.; Gill, Ryan M.

In: American Journal of Surgical Pathology, Vol. 41, No. 3, 01.01.2017, p. 365-373.

Research output: Contribution to journalArticle

Choi, Won Tak ; Jen, Kuang-Yu ; Wang, Dongliang ; Tavakol, Mehdi ; Roberts, John P. ; Gill, Ryan M. / Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection. In: American Journal of Surgical Pathology. 2017 ; Vol. 41, No. 3. pp. 365-373.
@article{0b7562939d2a43ddb3dd508776240558,
title = "Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection",
abstract = "Although donor livers with <30{\%} large droplet macrovesicular steatosis (MaS) and/or small droplet MaS (irrespective of percentage) are considered safe to use, this consensus is based on variable definitions of MaS subtypes and/or without a reproducible scoring system. We analyzed 134 donor liver biopsies from allografts transplanted at University of California at San Francisco between 2000 and 2015 to determine whether large and/or small droplet MaS is a risk factor for poor outcomes. Large droplet MaS was defined as a fat droplet occupying greater than one half of an individual hepatocyte, with nuclear displacement, and scored as the percentage of total parenchymal area replaced by large fat droplets on ×40 magnification. Small droplet MaS was defined as 1 to several discrete fat droplets, each occupying less than one half of an individual hepatocyte, and scored as the percentage of remaining hepatocytes (ie, hepatocytes not occupied by large fat droplets) containing small fat droplets on ×200 magnification (ie, small droplet MaS is the percentage of {"}remaining hepatocytes{"} with small fat droplets, and {"}remaining hepatocytes{"} is defined as 100{\%} minus percent large droplet MaS). Thus, total MaS equals the sum of large and small droplet MaS, which cannot exceed 100{\%}. Electronic medical records were reviewed to determine outcomes. There was an increased risk for acute cellular rejection (hazard ratio=2.5, P=0.0108) and bile duct loss suggestive of chronic ductopenic rejection (hazard ratio=2.4, P=0.0130) in donor livers with ≥30{\%} small droplet MaS. Large droplet MaS (up to 60{\%}) was not associated with adverse outcomes. Patient survival was not adversely affected by steatosis. Excellent agreement on the estimation of large (weighted κ=0.682) and small droplet MaS (weighted κ=0.780) was achieved. Our approach to donor steatosis scoring can identify liver allograft recipients at increased risk for rejection and highlights the importance of distinguishing between small and large droplet MaS in this evaluation.",
keywords = "donor liver, liver transplantation, rejection, steatosis",
author = "Choi, {Won Tak} and Kuang-Yu Jen and Dongliang Wang and Mehdi Tavakol and Roberts, {John P.} and Gill, {Ryan M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/PAS.0000000000000802",
language = "English (US)",
volume = "41",
pages = "365--373",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection

AU - Choi, Won Tak

AU - Jen, Kuang-Yu

AU - Wang, Dongliang

AU - Tavakol, Mehdi

AU - Roberts, John P.

AU - Gill, Ryan M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although donor livers with <30% large droplet macrovesicular steatosis (MaS) and/or small droplet MaS (irrespective of percentage) are considered safe to use, this consensus is based on variable definitions of MaS subtypes and/or without a reproducible scoring system. We analyzed 134 donor liver biopsies from allografts transplanted at University of California at San Francisco between 2000 and 2015 to determine whether large and/or small droplet MaS is a risk factor for poor outcomes. Large droplet MaS was defined as a fat droplet occupying greater than one half of an individual hepatocyte, with nuclear displacement, and scored as the percentage of total parenchymal area replaced by large fat droplets on ×40 magnification. Small droplet MaS was defined as 1 to several discrete fat droplets, each occupying less than one half of an individual hepatocyte, and scored as the percentage of remaining hepatocytes (ie, hepatocytes not occupied by large fat droplets) containing small fat droplets on ×200 magnification (ie, small droplet MaS is the percentage of "remaining hepatocytes" with small fat droplets, and "remaining hepatocytes" is defined as 100% minus percent large droplet MaS). Thus, total MaS equals the sum of large and small droplet MaS, which cannot exceed 100%. Electronic medical records were reviewed to determine outcomes. There was an increased risk for acute cellular rejection (hazard ratio=2.5, P=0.0108) and bile duct loss suggestive of chronic ductopenic rejection (hazard ratio=2.4, P=0.0130) in donor livers with ≥30% small droplet MaS. Large droplet MaS (up to 60%) was not associated with adverse outcomes. Patient survival was not adversely affected by steatosis. Excellent agreement on the estimation of large (weighted κ=0.682) and small droplet MaS (weighted κ=0.780) was achieved. Our approach to donor steatosis scoring can identify liver allograft recipients at increased risk for rejection and highlights the importance of distinguishing between small and large droplet MaS in this evaluation.

AB - Although donor livers with <30% large droplet macrovesicular steatosis (MaS) and/or small droplet MaS (irrespective of percentage) are considered safe to use, this consensus is based on variable definitions of MaS subtypes and/or without a reproducible scoring system. We analyzed 134 donor liver biopsies from allografts transplanted at University of California at San Francisco between 2000 and 2015 to determine whether large and/or small droplet MaS is a risk factor for poor outcomes. Large droplet MaS was defined as a fat droplet occupying greater than one half of an individual hepatocyte, with nuclear displacement, and scored as the percentage of total parenchymal area replaced by large fat droplets on ×40 magnification. Small droplet MaS was defined as 1 to several discrete fat droplets, each occupying less than one half of an individual hepatocyte, and scored as the percentage of remaining hepatocytes (ie, hepatocytes not occupied by large fat droplets) containing small fat droplets on ×200 magnification (ie, small droplet MaS is the percentage of "remaining hepatocytes" with small fat droplets, and "remaining hepatocytes" is defined as 100% minus percent large droplet MaS). Thus, total MaS equals the sum of large and small droplet MaS, which cannot exceed 100%. Electronic medical records were reviewed to determine outcomes. There was an increased risk for acute cellular rejection (hazard ratio=2.5, P=0.0108) and bile duct loss suggestive of chronic ductopenic rejection (hazard ratio=2.4, P=0.0130) in donor livers with ≥30% small droplet MaS. Large droplet MaS (up to 60%) was not associated with adverse outcomes. Patient survival was not adversely affected by steatosis. Excellent agreement on the estimation of large (weighted κ=0.682) and small droplet MaS (weighted κ=0.780) was achieved. Our approach to donor steatosis scoring can identify liver allograft recipients at increased risk for rejection and highlights the importance of distinguishing between small and large droplet MaS in this evaluation.

KW - donor liver

KW - liver transplantation

KW - rejection

KW - steatosis

UR - http://www.scopus.com/inward/record.url?scp=85008420122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008420122&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000802

DO - 10.1097/PAS.0000000000000802

M3 - Article

C2 - 28059835

AN - SCOPUS:85008420122

VL - 41

SP - 365

EP - 373

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 3

ER -